Novo Nordisk reported results from a late-stage trial indicating that a 7.2 mg weekly dose of semaglutide led to a 20.7% mean weight reduction in adults with obesity.

The trial included 1,407 participants and compared the 7.2 mg dose to the 2.4 mg dose and placebo. Both doses were administered weekly. The 7.2 mg dose demonstrated statistically significant weight loss superior to both the placebo and the 2.4 mg dose.

After 72 weeks, participants on the 7.2 mg dose experienced a mean weight loss of 20.7%, compared with 17.5% for the 2.4 mg dose and 2.4% for the placebo. Additionally, 33.2% of participants in the 7.2 mg group achieved ≥25% weight loss, compared with 16.7% in the 2.4 mg group.

Novo Nordisk stated that detailed results will be presented at a scientific conference in 2025. A second phase 3 trial evaluating the 7.2 mg dose in adults with obesity and type 2 diabetes is ongoing, with results expected in the coming months.